Literature DB >> 25303898

Gain of copy number and amplification of the RET gene in lung cancer.

Hai-Su Yang1, Bruce Horten2.   

Abstract

RET rearrangement represents a unique molecular subset of lung cancer. The identification of specific clinicopathologic characteristics and RET gene status would provide critical information on targeted therapeutics. In this study, we investigated the patterns of RET gene in a series of lung carcinomas. Of one hundred and sixteen tumors, a low frequency (1.7%) of RET translocation was identified. Only two specimens of lung adenocarcinomas displayed the rearrangement of RET in 54% and 78% of tumor cells respectively. A high incidence of gain of copy number (3-4 copies) and amplification (≥ 5 copies) of the RET gene was observed in 52% and 12% of all 116 samples. An association between increased copy number of RET and EGFR mutation was statistically significant (p < 0.05) in these lung carcinomas. This study sheds light on the unique molecular characteristics of the RET gene in lung carcinomas.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diagnosis; Lung cancer; RET

Mesh:

Substances:

Year:  2014        PMID: 25303898     DOI: 10.1016/j.yexmp.2014.10.002

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  7 in total

1.  Coexistent genetic alterations involving ALK, RET, ROS1 or MET in 15 cases of lung adenocarcinoma.

Authors:  Zhenya Tang; Jianjun Zhang; Xinyan Lu; Wei Wang; Hui Chen; Melissa K Robinson; Joanne Cheng; Guilin Tang; L Jeffrey Medeiros
Journal:  Mod Pathol       Date:  2017-09-15       Impact factor: 7.842

2.  Integrated analysis of gene expression and copy number identified potential cancer driver genes with amplification-dependent overexpression in 1,454 solid tumors.

Authors:  Keiichi Ohshima; Keiichi Hatakeyama; Takeshi Nagashima; Yuko Watanabe; Kaori Kanto; Yuki Doi; Tomomi Ide; Yuji Shimoda; Tomoe Tanabe; Sumiko Ohnami; Shumpei Ohnami; Masakuni Serizawa; Koji Maruyama; Yasuto Akiyama; Kenichi Urakami; Masatoshi Kusuhara; Tohru Mochizuki; Ken Yamaguchi
Journal:  Sci Rep       Date:  2017-04-04       Impact factor: 4.379

3.  Lamin B1 loss promotes lung cancer development and metastasis by epigenetic derepression of RET.

Authors:  Yanhan Jia; Joaquim Si-Long Vong; Alina Asafova; Boyan K Garvalov; Luca Caputo; Julio Cordero; Anshu Singh; Thomas Boettger; Stefan Günther; Ludger Fink; Till Acker; Guillermo Barreto; Werner Seeger; Thomas Braun; Rajkumar Savai; Gergana Dobreva
Journal:  J Exp Med       Date:  2019-04-23       Impact factor: 14.307

4.  The multi-targeted tyrosine kinase inhibitor vandetanib plays a bifunctional role in non-small cell lung cancer cells.

Authors:  Yan Zhou; Yuanliang Zhang; Hanbing Zou; Ning Cai; Xiaojing Chen; Longmei Xu; Xianming Kong; Peifeng Liu
Journal:  Sci Rep       Date:  2015-02-27       Impact factor: 4.379

5.  Molecular mechanisms of OLIG2 transcription factor in brain cancer.

Authors:  Igor F Tsigelny; Valentina L Kouznetsova; Nathan Lian; Santosh Kesari
Journal:  Oncotarget       Date:  2016-08-16

6.  Clinicopathological characteristics of ROS1- and RET-rearranged NSCLC in caucasian patients: Data from a cohort of 713 non-squamous NSCLC lacking KRAS/EGFR/HER2/BRAF/PIK3CA/ALK alterations.

Authors:  Frédéric Dugay; Francisco Llamas-Gutierrez; Marjory Gournay; Sarah Medane; François Mazet; Dan Christian Chiforeanu; Emmanuelle Becker; Régine Lamy; Hervé Léna; Nathalie Rioux-Leclercq; Marc-Antoine Belaud-Rotureau; Florian Cabillic
Journal:  Oncotarget       Date:  2017-06-08

7.  Expression and copy number gains of the RET gene in 631 early and mid stage non-small cell lung cancer cases.

Authors:  Ling Tan; Yerong Hu; Yongguang Tao; Bin Wang; Jun Xiao; Zhenjie Tang; Ting Lu; Hao Tang
Journal:  Thorac Cancer       Date:  2018-02-23       Impact factor: 3.500

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.